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Statement of clinical relevance: 
In spite of diagnosis and treatment improvements, lung cancer is the leading cause of death 
from cancer with a 10 years overall survival less than 10%. Although surgical resection of 
lung tumors restricted to the chest is in many cases the most effective method to control the 
disease, it might not be sufficient or curative for a proportion of patients with stage I NSCLC 
as inferred from 30% death within 5 years after surgery. The use of adjuvant chemotherapy is 
still a matter of debate for these patients. Several highthrouput analyses have suggested that 
stage I NSCLC might represent heterogeneous prognostic subgroups. In this study, by using a 
simple immunohistochemical approach with a specific antibody, we demonstrate that the 
status of histone H4K20 trimethylation stratifies patients with stage I adenocarcinoma tumors 
for risk of cancer death. Therefore, studying H4K20me3 status might represent a useful 
genomic tool to identify prognostic subgroups of stage I patients that could justify the use of 
adjuvant chemotherapy. 
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Abstract       
Purpose: Epigenetic modifications of Histones have crucial roles in the control of 
gene activity, nuclear architecture and genomic stability. In this respect they may contribute 
to the development and progression of cancer. We investigated whether epigenetic changes of 
histone H4 are involved in lung carcinogenesis.  
Experimental design: Epigenetic modifications of histone H4 were studied by 
immunohistochemistry (IHC) in normal lung and 157 lung carcinoma using antibodies 
specifically recognizing the acetylated (Ac) lysines 5 (K5), K8, K12, K16 and trimethylated 
(me3) K20 residues of histone H4.  Western blotting was used to validate the IHC results. 
H4K20me3 was also studied in 17 preneoplastic lesions. Expression of the Suv4-20h1/2 
trimethyltransferases was analyzed by quantitative RT/PCR in a subset of tumor samples. 
Results: As compared to normal lung, cancer cells displayed an aberrant pattern of 
histone H4 modifications with hyperacetylation of H4K5/K8, hypoacetylation of H4K12/K16 
and loss of H4K20 trimethylation. Alteration of H4K20 trimethylation was frequent in 
squamous cell carcinoma (67%) and was observed in early precursors lesions in which the 
level of H4K20me3 staining strongly decreased with disease progression. In adenocarcinoma, 
the downregulation of H4K20me3 was less frequent (28%) but allowed the identification of a 
subgroup of stage I adenocarcinoma patients with reduced survival (p=0.007). Loss of H4K20 
trimethylation was associated with decreased expression of Suv4-20h2, a specific H4K20 
trimethyltransferase involved in telomere length maintenance.  
Conclusions: Our findings indicate an important role of histone H4 modifications in 
bronchial carcinogenesis and highlight H4K20me3 as a candidate biomarker for early 
detection and therapeutic approaches of lung cancer.  
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Introduction 
 Lung cancer is the leading cause of death from cancer among males in Europe and 
both men and women in the USA. Non-small-cell lung cancer (NSCLC) accounts for almost 
80 percent of such deaths (1-3). In spite of diagnosis and treatment improvements, 10 years 
overall lung cancer survival is less than 10%, claiming more deaths than breast, colon and 
prostate cancers all together. Early diagnosis allowing surgical resection with a 60 to 80% 5 
years survival is performed in only less than 25% of the patients. Therefore, the identification 
of the molecular biomarkers of clonal selection in lung cancer as well as the comprehension 
of the mechanisms of their participation to the lung carcinogenesis process are required to 
establish the prognostic factors of progression of preneoplastic and invasive tumors towards 
earlier diagnosis, and to define more efficient therapies with lower side effects. 
Lung cancer is the end result of a process that associates multifocal morphological 
transformation and multistep accumulation of molecular abnormalities (4). The clonal 
selection leading to proliferation and invasion is achieved by disruption of the cell growth 
controls, with a tumor progression kinetic depending on the number and accumulation rate of 
these molecular alterations. Common genetic abnormalities in lung carcinogenesis include 
invalidation of tumor suppressor genes, activation of oncogenes and chromosomal 
abnormalities (5). Furthermore, it is now apparent that epigenetic modifications that do not 
affect the primary sequence of the DNA also contribute to lung tumor formation. These 
involve both global genomic hypomethylation leading to chromosomal instability, and 
regional hypermethylation at certain promoters (6-8). By this mechanism of silencing, the 
expression of tumor suppressor genes in the cancer cell can be reduced or eliminated as an 
alternative mechanism to genetic mutation. Chromatin modifications represent another 
mechanism of epigenetic regulation. They occur at the level of histones that are the targets for 
several post-translational covalent modifications which allow regulable contacts with the 
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underlying DNA and thus affect higher-order chromatin structures (9). In this regard, histone 
covalent modifications influence a multitude of cellular processes (10-12) and aberrant 
histone acetylation and methylation patterns were recently reported in human tumors (13, 14). 
Histone H4 is one of the nucleosomal core histones. Acetylation and methylation of lysine 
residues in its N-terminal tail have been reported to affect higher-order chromatin structure, 
transcriptional regulation and DNA repair, suggesting that alteration of these histone marks 
might play a role in tumorigenesis (12). Accordingly, loss of lysine 16 acetylation and lysine 
20 trimethylation has been recently shown in cancer cells from liver, breast and colon as well 
as in lymphoma (1, 14, 15). The aim of this study was to analyze the role of histone H4 
modifications in lung cancer. We examined the acetylation and methylation pattern of histone 
H4 in human normal lung and non small cell lung cancer by using immunohistochemistry and 
specific antibodies, and analyzed the relationships with clinico-parameters and clinical 
outcome. Our results demonstrate a global distorted pattern of histone H4 modifications in 
lung tumors and provide evidence that loss of H4K20 trimethylation plays a crucial role in 
lung tumorigenesis.  
 
Materials and methods 
Patients and tissue samples 
 Patient selection was based on consecutive collection of cases in the tumor bank 
balanced between histo-pathological subtypes, and completeness of clinical data (date and 
cause of death, at least 5 years of follow up, absence of chemotherapy given before or after 
surgical resection). One hundred and fifty seven human lung tumors were included in this 
study. Tissue samples were taken at surgical resection of lung tumors in all cases. Tumor 
tissue and normal lung parenchyma taken at distance from the bulk of the tumor were 
immediately frozen and stored at -80°C until use. For histological classification, tumor 
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samples were fixed in formalin and diagnosis was made on paraffin-embedded material using 
the current World Health Organization International Classification of lung criteria (16). They 
consisted of 50 squamous cell carcinoma (13 stage I, 11 stage II, 25 stage III and 1 stage IV) 
and 107 adenocarcinoma (80 stage I, 7 stage II, 17 stage III and 3 stage IV). Tumors were 
used according to the ethical laws of our country. The median time of follow up calculated by 
the Schemper and Smith method (17) was 67 months. Bronchial intraepithelial preinvasive 
lesions were obtained from lung resection performed for lung cancer in 7 patients. Preinvasive 
lesions were classified according to the WHO classification criteria (16). Squamous 
metaplasia and mild dysplasia were considered as low-grade dysplasia, whereas moderate 
dysplasia, severe dysplasia and CIS were considered as high-grade dysplasia. 
 
Immunohistochemistry    
 Seven-micrometer-thick serial frozen sections were incubated at 42°C with primary 
antibodies anti-acetylated H4K5 (Abcam ab1758, 1/100), anti-acetylated H4K8 (Abcam 
ab1760, 1/2000, anti-acetylated H4K12 (Upstate 06-761, 1/750), anti-acetylated H4K16 
(Abcam ab1762, 1/400) and anti-trimethylated H4K20 (Upstate 07-463, 1/800). Fixation was 
with 3.7% paraformaldehyde for 10 minutes. A three-stage indirect immunoperoxidase 
technique was performed using the Ventana Discovery Autostainer (Ventana Medical 
International Inc.Tuscon, AZ, USA) which garanties full reproducibility of immunostaining. 
Negative control consisted in omission of the primary antibody and incubation with 
immunoglobulins of the same species and isotype. Immunostaining was performed on whole 
sections and evaluated independently by two pathologists (EB, SL) who were blinded to all 
clinico-pathological variables (E.B, S.L). Selectivity and validation of the antibodies was 
ensured by recognition of different pattern of stained cells for 
H4K5Ac/K8Ac/K12Ac/K16Ac/K20me3 on serial sections of 3 microns intervals, as well as 
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on tumor blots. Reproducibility of staining was validated in 10 cases stained at several days 
interval times : the variability between the two score assessments by pathologists was less 
than 10% of global score. Scores of staining were ascribed to each case and antibody by 
multiplying the percentage of positive cells (0 to 100%) by the staining intensity (0, null; 1, 
faint; 2, moderate; 3, strong). They ranged from 0 to 300. Normal bronchi and alveolar 
epithelial cells were used as positive internal controls. These normal structures exhibited low 
staining scores for acetylated H4K5/K8 (20 and 40 respectively) and high staining scores for 
acetylated H4K12/16 and trimethylated H4K20 (300, 240 and 250 respectively). 
 
Immunoblotting 
Immunoblotting was performed on 15 representative tumor samples and their matched 
normal lung tissues. Proteins were extracted from sections taken at the immediate vicinity of 
those studied by immunohistochemistry. Immunoblotting experiments were performed as 
previously described (18) with the same antibodies used for immunohistochemistry. Dilutions 
of the primary antibodies were 1:500 for acetylated H4K5 and 1/1000 for acetylated 
H4K8/K12/K16 and trimethylated H4K20 antibodies. To ensure equal loading and transfer of 
proteins, the membranes were subsequently probed with a polyclonal actin antibody (1:500; 
Sigma-Aldrich; L’Isle d’Abeau).  
 
RT-QPCR 
Total RNA was extracted from normal and human lung tumors samples using RNeasy Mini 
Kit (Qiagen), according to the manufacturer’s instructions. RNA concentration was 
determined using Eppendorf Biophotometer AG22331 (Hamburg, Germany) and RNA 
integrity was assessed using the Agilent Bioanalyzer 2100 (Agilent Technologies, 
Waldbronn, Germany). Quantitative real-time RT-PCR for Suv4-20H1 and Suv4-20H2 
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mRNA (genbank acc. no. NM_017635 and NM_032701) was performed on Stratagene 
MX3005P apparatus. 1µg of total RNA were subjected to cDNA synthesis with Superscript 
III First-Strand Synthesis SuperMix for qPCR (Invitrogen) and subsequently amplified during 
40 PCR cycles (10 min at 95°C, cycles: 15 s at 95°C, 1 min at 60°C) using Power SYBR 
Green PCR Master Mix (Applied Biosystems) The specific primers used for mRNA 
amplification were as follows: Suv4-20H1 forward: 5’- CGC CCT GCA CCT ACA TAA CT-
3’; reverse: 5’-ACA CTT TGC CTC CCC TTT TT-3’; Suv4-20H2 forward: 5’-CGG TGA 
GAA TGA CTT CAG CA-3’; reverse: 5’-CTC ACA GGT GTG GCA TTC AC. In parallel, 
RT-PCR detecting the reference gene Glyceraldehyde-3-Phosphate Deshydrogenase 
(GAPDH) was performed for each sample. Relative gene expression was calculated for each 
sample, as the ratio of Suv4-20H1 or Suv4-20H2 copy number (target gene) to GAPDH 
mRNA copy number multiplied by 100, thus normalizing Suv4-20H1 or Suv4-20H2 mRNA 
expression for sample to sample differences in RNA input. 
 
Statistical analyses 
To test whether variables were correlated within patients, we used the Spearman test. 
Descriptive analyses comparing continuous and two-level categorical variables were carried 
out using Mann Whitney test. The chi-2 test was used to test the association between two 
categorical variables. Overall survival was calculated from the date of surgery to the last day 
of follow-up or cancer death. Univariate survival analyses were performed using the Kaplan-
Meier method and the log-rank test. Statistics were performed using Statview 4.1 software 
(Abacus Concept Inc, Ca). A p-value of less than 0.05 was considered statistically significant. 
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Results 
Global modification of histone H4 acetylation in lung cancer 
 One hundred non small cell lung cancers comprising 50 squamous carcinoma and 50 
adenocarcinoma were analyzed by immunohistochemistry (IHC) using antibodies specifically 
recognizing the acetylated (Ac) lysines 5 (K5), K8, K12 or K16 residues of histone H4. Low 
levels of nuclear H4K5Ac and H4K8Ac staining were found in normal lung parenchyma 
adjacent to or distant from tumor bulk, whereas high levels of immunostaining were observed 
for H4K12Ac and H4K16Ac (Figure 1 and supplementary Figure 1). Therefore, these data 
show that the lysine residues of the H4 tail exhibit a differential pattern of acetylation in the 
normal lung.  
 As compared to normal lung parenchyma, the study of lung tumors revealed a general 
increase of H4K5Ac/K8Ac expression (Figure 1, panels a and b) and decrease of 
H4K12Ac/16Ac expression (Figure 1, panels c and d). The IHC data were validated for each 
antibody by immunoblotting in 15 representative tumor samples and their matched normal 
lung tissues. Figure 1 (middle) illustrates an example of the results. As compared to normal 
lung, acetylation of H4K16 was clearly downregulated in lung tumors with more than 70% of 
samples displaying a score between 0 and 100 (Figure 1, right panel). Distribution of 
H4K16Ac staining was very similar between both histological types (Figure 2). By contrast, a 
broader distribution of H4K5Ac, H4K8Ac and H4K12Ac stainings was observed. 
Furthermore, high levels of H4K5Ac and H4K8Ac were more frequent in squamous cell 
carcinoma whereas low levels of H4K12Ac were predominantly observed in adenocarcinoma 
(Figure 2, Mann Whitney, p=0.016, p<0.0001 and p=0.0007 respectively). A strong 
association between H4K8Ac and H4K12Ac was observed in squamous cell carcinoma 
(Spearmann’s correlation coefficient, r=0,6038; p<0.0001) whereas H4K12Ac and H4K16Ac 
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were correlated in adenocarcinoma (Spearmann’s correlation coefficient, r=0,49; p=0.0009). 
A strong association between H4K5Ac and H4K8Ac (Spearmann’s correlation coefficient, 
r=0,409; p<0.0001) or H4K5Ac and H4K12AC (Spearmann’s correlation coefficient, 
r=0,347; p=0.0007) was also found independently of the histological type. The significance of 
these correlations is still unclear but could reflect a thorough crosstalk between histone H4 
modifications as recently described for histone H3 (19, 20). No additional significant 
relationships were observed between H4K5/K8/K12/K16Ac stainings and clinico-parameters 
(stage, clinical outcome).  
 
Loss of trimethylation at H4K20 in lung tumors. 
 The same series of lung carcinoma was studied for histone H4 lysine 20 trimethylation 
(H4K20me3) by immunohistochemistry using a specific anti- trimethylated K20 antibody. As 
shown in Figure 3A, a global loss of H4K20me3 was observed in lung tumors (panel b) as 
compared to normal lung that expressed strong H4K20me3 staining (panel a). These results 
were confirmed by western blotting in representative cases (Figure 3B). The distribution of 
H4K20me3 staining scores showed that 70% of the tumor samples had a H4K20me3 score 
between 0 and 100 (Figure 3C). As the mean score of the normal lung was 250, it can be 
stated that trimethylation of H4K20 is frequently and strongly decreased in lung tumors. 
Strikingly, loss of H4K20me3 was more frequent in squamous carcinoma than in 
adenocarcinoma (Figure 3D, Mann Whitney, p<0.0001). Moreover, a strong inverse 
association between H4K8Ac and H4K20me3 modifications was detected in adenocarcinoma 
(Spearmann’s correlation coefficient, r=-0.487; p=0.0008).  
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Trimethylation at H4K20 is lost in squamous preneoplasia. 
 Trimethylation of H4K20 was strongly downregulated in squamous carcinoma as 
revealed by the distribution of H4K20me3 scores (67% of cases with a score <60, Figure 3D 
and 4A). In these tumors, no relationship was observed between H4K20me3 IHC status and 
stage or clinical outcome but we noticed that a large proportion (69%) of stage I tumor 
samples exhibited very low levels of H4K20me3 (score<60). This led us to investigate the 
possibility that this histone modification could take place early during squamous 
carcinogenesis. Stepwise morphological changes accompanying this transformation process 
have been described in smokers and include squamous hyperplasia (H), metaplasia (M), 
dysplasia (D) of progressive severity (mild, moderate and severe) and carcinoma in situ (CIS) 
(21). According to the criteria provided by the WHO classification of lung cancers and 
precursors, metaplasia, dysplasia and CIS represent preinvasive lesions of the bronchial 
epithelium (16) whereas basal hyperplasia are very common reactive lesions in adults. To 
assess whether loss of trimethylation at H4K20 might be involved in the development of 
squamous cell carcinoma, we analyzed its IHC status in a series of 18 preinvasive lesions 
observed in 7 surgical resection frozen specimens for cancer. They consisted of 4 basal 
hyperplasia, 4 metaplasia, 2 mild dysplasia, 2 moderate dysplasia, 2 severe dysplasia and 4 
CIS. As compared to normal bronchial epithelium in which basal cells exhibited a strong 
nuclear staining, we noticed that hyperplasia displayed a less intense H4K20me3 
immunostaining with the appearance of some negative nuclei. Strikingly, the level of 
H4K20me3 strongly decreased with disease progression from cell hyperplasia to metaplasia, 
dysplasia (mild, moderate, severe) and then to CIS (Figure 4, B and C). Therefore, these 
results demonstrate that trimethylation of H4K20 is lost in early precursors lesions of 
squamous cell carcinoma.  
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Loss of H4K20me3 correlates with a poor survival in stage I adenocarcinoma patients 
 In contrast with squamous cell carcinoma, the downregulation of H4K20me3 was less 
frequent in adenocarcinoma (28% of cases with a score <60, Figure 3D). Interestingly, the 
distribution of H4K20me3 scores clearly identified two populations of stage I 
adenocarcinoma tumor samples with distinct clinical outcome, a longer cancer related 
survival being observed for patients whose tumors expressed higher levels (score > 100) 
(Figure 5A, p=0.0125). To validate the prognostic power of H4K20me3 in early stage 
adenocarcinoma, we studied H4K20me3 immunostaining in another set of stage I 
adenocarcinoma. Analysis of these new series of 57 stage I adenocarcinoma samples 
confirmed the existence of two distinct H4K20me3 staining groups (Figure 5B). According to 
Kaplan-Meier analysis recording cancer related death, 30% of low H4K20me3 staining 
carriers (score ≤ 100) had died from lung cancer at 5 years after diagnosis compared with 5% 
of noncarriers. The median survival time for low H4K20me3 carriers was 114 ± 2.8 months, 
whereas it was not reached for patients who had high H4K20me3. Therefore, carrying low 
levels of H4K20me3 was associated with reduced survival for patients with stage I 
adenocarcinoma as compared to cases with high levels of H4K20me3 (p = 0.024). Finally, the 
influence of loss of H4K20 trimethylation was evaluated on the all stage I population 
combining test series and validation cases. In this population of 80 stage I adenocarcinoma, 
the median survival time was 140 ± 4 months. The results showed that low H4K20me3 
staining correlated with shorter cancer related survival (median 114 ± 2.8) as compared to 
cases with high H4K20me3 staining (median non reached, p=0.007).  Age (<60 years versus 
>60 years), sex (male versus female) and T stage (IA versus IB) were not associated with 
survival in univariate analyses. Thus, we did not associate these variables to H4K20me3 in a 
multivariate Cox proportional hazard model. 
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Loss of Suvar4-20h2 expression correlates with reduced H4K20me3 
 Mechanistic basis of H4K20me3 modification may be related to altered expression of 
various histone-modifying enzymes. Enzymes that demethylate H4K20 have not yet been 
identified. By contrast, it is well-known that trimethylation of histone H4 lysine 20 is 
catalysed by the histone methyltransferases (HMTases) Suv4-20h1/2 (also called KMT5B/C) 
(22). To uncover the mechanisms involved in H4K20me3 deregulation in lung tumors, we 
analyzed the expression of suvar4-20h1/2 HMTases. Because available Suv4-20h1/2 
antibodies did not work for immunohistochemical application in our hands, we performed 
quantitative RT/PCR analysis. Total RNA was extracted from 31 representative tumor 
samples exhibiting either very low (! 60) or very high ("210) scores of H4K20me3 according 
to IHC, as well as from their matched normal lung. Tumors were considered having an altered 
expression of Suv4-20h1 or Suv4-20h2 when a modification of at least 50% of the transcript 
level was observed as compared to matched normal lung. The data showed that 68% (21/31) 
and 55% (17/31) of tumor samples had a decreased level of Suv4-20h1 and Suv4-20h2 
transcripts respectively as compared to normal lung (Table 1), thereby indicating that 
expression of Suv4-20h transcripts is globally downregulated in lung tumors. Importantly, we 
observed that low levels of H4K20me3 were associated with a decrease of Suv4-20h2 
transcripts (p=0.019). By contrast, no significant association was found between H4K20me3 
staining and Suv4-20h1 mRNA level (p=0.37). Altogether these results suggest that alteration 
of Suv4-20h2 expression might play a role in the deregulation of H4K20 trimethylation in 
lung tumors. 
 
Discussion 
 The prognosis of lung cancer is affected by the difficulties of diagnosing early stage 
disease amenable to surgery. Thus, novel diagnostic, risk assessment and therapeutic 
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approaches are urgently needed for this common and devastating cancer. Epigenetic has 
become an increasingly important aspect of cancer biology. Epigenetic changes encompasse 
an array of molecular modifications to both DNA and chromatin, the most extensively 
investigated of which is DNA methylation. Recently, aberrant histone acetylation and 
methylation patterns have been reported in tumors (13, 14), suggesting that perturbation in 
chromatin structure may also contribute to tumorigenesis. In this study, we show that lung 
tumors exhibit an altered pattern of histone H4 modifications as compared to normal lung. 
Furthermore, we demonstrate that trimethylation at lysine 20 of histone H4 is dramatically 
reduced in squamous preneoplastic lesions and provide evidence that loss of H4K20me3 
predicts a bad prognosis for patients with early stage adenocarcinoma. Altogether, our results 
highlight the role of chromatin disorders in lung carcinogenesis and support the idea that post-
translational modifications of histone H4 are relevant steps in the lung transformation process. 
It is becoming clear that aberrant modification of histones can play a major role during 
the multistep process of cancer development. In this study we show that human lung tumors 
display a clear downregulation of H4K20 trimethylation. As loss of H4K20 trimethylation has 
been reported in lymphoma, colon and breast cancer as well as in various cancer cell lines 
(14, 15), our results are consistent with the notion that aberrant H4K20me3 is a common 
hallmark of human cancer. Adenocarcinoma and squamous carcinoma are the main 
histological subtypes of non-small-cell lung cancer. They can be distinguished not only on the 
basis of pathological features but also by distinct molecular alterations that contribute to their 
development. This is best illustrated by the quite selective occurrence of Ras and EGFR 
mutations in adenocarcinoma (5). In this study, we demonstrate that aberrant H4K20 
trimethylation is frequent in squamous carcinoma and occurs early in preneoplastic precursors 
lesions in which the level of H4K20me3 strongly decreases along the sequential progression 
from cell hyperplasia to metaplasia, dysplasia and then to carcinome in situ. In contrast, 
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whereas altered trimethylation of H4K20 is less frequent in adenocarcinoma, it was found to 
influence the disease outcome. Altogether, these data support the idea that aberrant 
trimethylation of H4K20 might play a role in the early steps of squamous carcinoma 
development, whereas it could contribute to the progression and aggressivity of 
adenocarcinoma. However, we have not excluded the possibility that atypical adenomatous 
hyperplasia, the precursors lesions of adenocarcinoma with bronchioloalveolar features, 
display loss of H4K20 trimethylation. These lesions are not available in frozen lung tissue, a 
requirement for our antibody performance. 
The mechanism involved in the loss of H4K20me3 is not yet elucidated. Two histone 
methyltransferases (HMTases), namely Suv4-20h1/2, are responsible for H4K20 
trimethylation (22). Importantly, we demonstrate that loss of H4K20me3 is associated with a 
decrease of Suv4-20h2 transcripts. These data suggest that disruption of Suv4-20h2 
expression might contribute to altered H4K20me3 pattern at least in lung tumors. Although 
we cannot exclude the possibility that yet unidentified demethylase(s) specific for H4K20me3 
might be abnormally expressed in cancer cells, it is important to notice that similar correlation 
between H4K20me3 and Suv4-20h2 expression has been previously reported in human breast 
cancer cell lines as well as in a model of hepatocarcinogenesis induced by methyl deficiency 
in rats (1, 15).  
Approximately 45% of all lung carcinoma are limited to the chest, where surgical 
resection is not only an important therapeutic modality, but in many cases, the most effective 
method to control the disease. However, surgical treatment might not be sufficient or curative 
for a proportion of patients with NSCLC and especially adenocarcinoma, as inferred from 
30% death within 5 years after surgery at stage I. Adjuvant chemotherapy is presently 
considered as a standard of care since beneficial effects have been demonstrated in stages IIA 
to IIIA (23). However, some controversies still exist over the impact of adjuvant 
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chemotherapy in stage IB (24, 25). Based on a gene expression profile called the lung 
metagene model, Potti et al has identified a subgroup of patients with stage IA disease who 
were at high risk for recurrence (26), thereby indicating that stage I NSCLC might represent 
heterogeneous prognostic subgroups. Recently, acetylation of H3K9 was reported to predict 
outcome of patients with stage I adenocarcinoma (27). In this study we demonstrate that loss 
of histone H4K20 trimethylation correlates with a poor survival for stage I adenocarcinoma 
patients. Altogether these data indicate that histone modifications might represent useful 
genomic tools to identify prognostic subgroups of patients that could justify the use of 
adjuvant chemotherapy, and suggest that analysis of combined histone modifications may 
help to better define prognostic subgroups. Further prospective studies are now required to 
evaluate their predictive power to chemosensitivity.  
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Figure legends 
Figure 1 Global modification of histone H4 acetylation in lung tumors 
Left panel: immunostaining of lung cancer tissue on frozen sections using anti-acetylated 
H4K5, H4K8, H4K12 and H4K16 antibodies (immunoperoxidase, X200). Strong nuclear 
staining of acetylated H4K5 (a) and H4K8 (b) in squamous cell carcinoma. Low nuclear 
staining of acetylated H4K12 (c) and H4K16 (d) in squamous cell carcinoma and 
adenocarcinoma respectively. Middle panel: representative western blots showing high level 
of acetylated H4K5/K8 and low level of acetylated H4K12/K16 in lung tumors as compared 
to their matched normal lung tissues. Hybridization with actin antibody was used as a loading 
control. Right panel: distribution of staining for the four antibodies across all the 100 tumor 
samples. The y-axis is the fraction of samples showing the indicated score of staining (x axis). 
 
Figure 2 Distribution of H4K5Ac, H4K8Ac, H4K12Ac and H4K16Ac staining scores 
according to histological type of lung tumors. Statistical analyses were performed using a 
Mann-Whitney test. 
 
Figure 3 Global modification of H4K20 trimethylation in lung tumors. 
A, Immunostaining of norma l lung parenchyma and lung cancer tissue on frozen sections 
using anti-trimethylated H4K20 antibody. (immunoperoxidase, X200) (a). Strong nuclear 
staining of trimethylated H4K20 is observed in normal lung parenchyma, (b). Loss of 
H4K20me3 staining in an adenocarcinoma B, Representative western blot showing decreased 
expression of trimethylated H4K20 in lung tumors as compared to their matched normal lung 
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tissues. Hybridization with actin antibody was used as a loading control. C, Distribution of 
H4K20me3 staining across all the 100 tumor samples. The y-axis is the fraction of samples 
showing the indicated score of staining (x axis). D, Distribution of H4K20me3 scores 
according to histological type of lung tumors. Statistical analysis was performed using a 
Mann-Whitney test. 
 
Figure 4  Modification of H4K20 trimethylation in squamous preinvasive lesions  
A, Distribution of H4K20me3 staining across squamous cell carcinoma. The y-axis is the 
fraction of samples showing the indicated score of staining (x axis). B, Distribution of 
H4K20me3 staining across squamous preinvasive lesions. The y-axis is the score of 
H4K20me3 staining for the indicated preinvasive lesions (x axis). N, normal lung; H, 
hyperplasia; M, metaplasia; miD, mild dysplasia; moD, moderate dysplasia; sD, severe 
dysplasia; CIS, carcinoma in situ. C, Immunostaining on frozen sections of squamous 
preneoplasia from patient 7 using anti trimethylated H4K20 antibody. (a), strong nuclear 
immunostaining in normal bronchial epithelium. (b), immunostaining in hyperplastic 
bronchial epithelium. Note the absence of staining in some suprabasal cells. (c), 
immunostaining in a moderate dysplasia surrounded by severe dysplasia. Note the strong 
positive staining of epithelial cells above dysplastic cell. (d), immunostaining in a severe 
dysplasia. (e), immunostaining in CIS. (f), immunostaining in invasive carcinoma. (a,f), 
immunoperoxidase staining, X200. 
 
Figure 5  H4K20me3 influences survival of patients with stage I adenocarcinoma 
A, tested series of 23 stage I ADC patients, B, validation series of 57 independent stage I 
ADC patients, C, global population of stage I ADC patients combining test series and 
validation cases (80 cases). A,B,C left panel, distribution of H4K20me3 staining identifies 
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two groups of tumors with low (!100) or high (>100) H4K20me3 score. The y-axis is the 
fraction of samples showing the indicated score of staining (x axis). Right panel, Kaplan-
Meier analysis recording cancer related death of the two groups of patients according to high 
(>100) or low (!100) H4K20me3 score. 
 
 
Table1. Correlation between H4K20me3 and Suv4-20h1/2 status in lung tumors
          Suv4-20h1**            Suv4-20h2**
Nl low Nl low
high 6 9 10 5
H4K20me3* p = 0.37 p = 0.019
low 4 12 4 12
*Immunohistochemical score, high !210, low "60, ** expression level according RT-QPCR; NL, Normal, low "50, Chi
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